SEATTLE, May 10, 2023 /PRNewswire/ — CTI BioPharma CTIC (“CTI”), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB SOBI (“Sobi”), a global healthcare leader in…Read More
Sobi to Acquire CTI BioPharma CTI BioPharma NASDAQCTIC
